Small Biotech Earnings Day: Palvella's FDA Priority Review and Akebia's Vafseo Growth Amid Revenue Miss

The Quick Take

• Palvella Therapeutics (PVLA) Q3 net loss of $24.6M as FDA grants Priority Review for QTORIN Rapamycin — February 2027 decision on track
• Akebia Therapeutics (AKBA) Q3 revenue $36.9M misses $46.94M estimate but Vafseo patient counts surge ~140% year-over-year
• Both companies illustrate classic clinical-stage biotech dynamics — quarterly losses offset by pipeline progress that determines long-term value

Palvella Therapeutics (NASDAQ: PVLA) reported a Q3 2026 net loss of $24.6 million — GAAP EPS of -$1.70 — consistent with the cash-burning profile of a clinical-stage company advancing its lead asset toward an FDA decision. The critical catalyst in Palvella's Q3 update is the FDA's granting of Priority Review status to QTORIN Rapamycin, the company's investigational therapy targeting a rare disease indication. Priority Review, which shortens the standard 12-month FDA review to approximately 6 months, puts QTORIN on track for a potential approval decision by February 2027. For Palvella shareholders, this is the defining event in the company's near-term history — an approval transforms it from a clinical-stage company into a commercial-stage one, fundamentally altering the investment risk profile.

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 2026 revenue of $36.9 million — missing the $46.94 million analyst consensus by a meaningful margin — alongside a net loss of $14.4 million. The revenue miss was driven primarily by declining Auryxia sales as generic competition erodes the branded iron deficiency anaemia treatment's market share. However, the standout positive metric is the approximately 140 percent year-over-year growth in Vafseo patient counts — Vafseo (vadadustat) is Akebia's hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anaemia in chronic kidney disease patients on dialysis. The Vafseo patient count trajectory, while not yet reflected in revenue at scale, represents the demand signal that investors need to see before the product can deliver sustainable commercial success.

Both Palvella and Akebia represent distinct points on the clinical-to-commercial biotech continuum: Palvella is approaching a potential FDA approval gate that is the dominant value driver, while Akebia is managing a commercial launch that is gaining patient traction but faces revenue pressure from legacy product decline. For small-cap biotech investors, these Q3 results highlight the asymmetric risk-reward that characterises the category — quarterly losses are largely expected and unremarkable, while regulatory and commercial milestones are the events that drive material price appreciation or decline. The key monitor for Palvella is the February 2027 FDA decision; for Akebia, it is the pace of Vafseo revenue conversion from patient count growth.

Synthesized from 2 sources covering Palvella Therapeutics (PVLA) and Akebia Therapeutics (AKBA) Q3 2026 earnings.